Efficacy of ceftazidime–avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2
- 30 November 2017
- journal article
- research article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 30 (2) , 95-100
Abstract
Efficacies of ceftazidime–avibactam (4:1 w/w) and ceftazidime were tested against ceftazidime-susceptible (blaKPC-2-negative), and meropenem- and ceftazidime-resistant (blaKPC-2-positive), Klebsiella pneumoniae in a 52-h, multiple dose, abdominal abscess model in the rat. Efficacies corresponded to minimum inhibitory concentrations (MICs) measured in vitro and were consistent with drug exposures modelled from pharmacokinetics in infected animals. The ceftazidime, ceftazidime–avibactam and meropenem control treatments were effective in the rat abscess model against the susceptible strain, whereas only ceftazidime–avibactam was effective against K. pneumoniae harbouring blaKPC-2.Keywords
Funding Information
- AstraZeneca
This publication has 18 references indexed in Scilit:
- Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-LactamasesAntimicrobial Agents and Chemotherapy, 2014
- In Vivo Efficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae IsolatesAntimicrobial Agents and Chemotherapy, 2014
- Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2014
- Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2014
- Kinetics of Avibactam Inhibition against Class A, C, and D β-LactamasesJournal of Biological Chemistry, 2013
- Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trialJournal of Antimicrobial Chemotherapy, 2013
- Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumoniaJournal of Antimicrobial Chemotherapy, 2012
- Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-Producing Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2011
- In Vitro Activity of NXL104 in Combination with β-Lactams against Klebsiella pneumoniae Isolates Producing KPC CarbapenemasesAntimicrobial Agents and Chemotherapy, 2009
- Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic ratsAntimicrobial Agents and Chemotherapy, 1987